|10th Annual Neurotech Investing & Partnering Conference|
|Date:||Tuesday, April 7|
|Time:||3:30pm Pacific Time|
|Location:||Hotel Nikko, San Francisco|
|Presenter:||David Baker, Chief Commercial Officer|
|Neurology Innovation Conference|
|Date:||Sunday, April 19|
|Time:||3:30pm Eastern Time|
|Location:||Embassy Suites, Washington DC|
|Presenter:||Jonathan Rubin, MD, MBA, Chief Medical Officer|
Shares of Alcobra Ltd closed last Thursday at $5.69 . ADHD has a 1-year high of $22.19 and a 1-year low of $3.12. The stock's 50-day moving average is $6.58 and it's 200-day moving average is $6.26.
On the ratings front, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on ADHD, with a price target of $10, The current price target implies an upside of 75.7% from current levels, In a report issued on February 23. The current price target implies an upside of 75.7% from current levels
According to TipRanks.com, Chattopadhyay has a total average return of 12.2%, a 42.7% success rate, and is ranked #423 out of 3568 analysts.
Alcobra Ltd is a biopharmaceutical company which engaged in the development and commercialization of its proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome.